Safety of braf+mek inhibitor combinations: Severe adverse event evaluation

Keyphrases

• Severe Adverse Events 100%
• Inhibitor Combination 100%
• B-Raf 100%
• Event Evaluation 100%
• MEK Inhibitor (MEKi) 100%
• BRAF Inhibitor (BRAFi) 90%
• Reporting Odds Ratio 40%
• Serious Adverse Events 20%
• Pharmacovigilance 20%
• Dabrafenib 20%
• Vemurafenib 20%
• Cobimetinib 20%
• Trametinib 20%
• Binimetinib 20%
• Encorafenib 20%
• System Data 10%
• Patient Care 10%
• Patient Health 10%
• Safety Profile 10%
• Combination Therapy 10%
• Renal Disease 10%
• Fatal Outcome 10%
• Fever 10%
• Age-adjusted 10%
• Melanoma Patients 10%
• Peripheral Neuropathy 10%
• Severe Outcomes 10%
• BRAF V600E mutation 10%
• Skin Toxicity 10%
• Specific Safety 10%
• FDA Adverse Event Reporting System (FAERS) 10%
• Class Effect 10%
• Safety Signal 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 100%
• Pharmacovigilance 50%
• Syndrome 50%
• Vemurafenib 50%
• Dabrafenib 50%
• Trametinib 50%
• Binimetinib 50%
• Encorafenib 50%
• Cobimetinib 50%
• Melanoma 25%
• Kidney Disease 25%
• Fatality 25%
• Mitogen Activated Protein Kinase Kinase Inhibitor 25%
• Skin Toxicity 25%
• Combination Therapy 25%
• Peripheral Neuropathy 25%